Foundations call for early detection, preventive intervention as suicides spike
South Korea saw its largest number of suicide deaths in 13 years last year, but local welfare foundations and suicide prevention agencies feel more support is required to respond to the problem.
According to preliminary data from Statistics Korea released in late February, 14,439 suicides were reported last year — an average of nearly 40 each day.
This is the highest figure since the 15,906 deaths recorded in 2011.
South Korea's suicide rate, calculated as the number of suicides per 100,000 people, rose to 28.3 in 2024, the highest since 2013.
South Korea's suicide rate has been the highest among the 38 OECD countries since 2018, when it overtook Lithuania, according to the OECD Health Statistics.
The government has made several attempts at suicide prevention, including an increase in the number of local health centers, more suicide prevention campaigns and social media-based counseling. However, those who work closely with the cases insist that more practical, preemptive measures need to be discussed.
'Many policies are closely related to services for those who have attempted suicide in the past or bereaved family members. But it is essential to establish a stronger system for early detection and preventive intervention,' Life Insurance Philanthropy Foundation official Kang Soo-yeon told The Korea Herald.
The official also added that a lack of workers and regional disparities in support are other major difficulties.
She explained that economic difficulties, problems with interpersonal relationships, and underlying and related mental health issues have been primary causes linked to suicide deaths. But, uncertainty about one's future, unemployment, academic pressure and social isolation have emerged as new factors as well.
'As the major causes of suicide vary by time and social changes, more efforts are needed to thoroughly analyze the cases and make practical countermeasures to respond to rising concerns over suicide deaths,' Kang said.
The Korea Foundation for Suicide Prevention also emphasized the significance of preventive measures, especially citing the rise in provocative, suicide-themed online content.
The number of posts reported to authorities containing information about group suicide, items to use, and ways to lure others into self-harm or suicide increased from 32,588 to 303,636 cases from 2019 to 2023, respectively.
The agency believes that recognizing the seriousness and harmful impact of this content is essential to creating an environment where people understand the importance of life and promote self-care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 days ago
- Korea Herald
Radon risk returns as mattress safety lags
Simmons remains only brand with full radon certification, while Sealy's top premium lines remain uncertified despite past recall South Korea's mattress industry is showing signs of complacency regarding radon gas safety certifications, despite a deadly scandal that rocked the nation in 2018. Radon is the second-leading cause of lung cancer after smoking. According to the Korean Standards Association on Tuesday, Simmons — Korea's top-selling mattress brand — remains the only company in the country to have obtained radon safety certification for its entire product lineup. Another popular mattress brand, Australia's Sealy, has also received certification from the agency, but its two flagship premium lines, the Haynes and Crown Jewel, remain uncertified. In 2019, Sealy Korea recalled more than 350 products manufactured between January 2014 and November 2016 after the state-run Nuclear Safety and Security Commission detected radon — a Group 1 carcinogen classified by both the World Health Organization and the US Environmental Protection Agency. This followed the 2018 revelation that mattresses made by Korea's Daijin Bed Co. emitted radon at levels far exceeding safety limits. Although Sealy claimed that all of its products had since obtained radon safety certification, it faced public backlash in recent years when this was found to be untrue. In response, Sealy secured KSA safety certification for 92 products — excluding the two premium models — at the end of last year. Sealy maintains that its Haynes and Crown Jewel lines have already met strict eco-friendly standards overseas. The company argues that since the KSA's radon certification is voluntary and not legally required, there is no pressing need to certify its entire product line. However, industry insiders argue that Sealy should take the issue more seriously, citing the ongoing fallout from the Daijin Bed scandal. Daijin effectively ceased operations in 2019, but out of approximately 280,000 radon-contaminated mattresses and related products, fewer than half — around 130,000 units — have been retrieved, according to sources. 'Even if Sealy holds international certifications, those don't automatically apply in Korea,' said Cho Seung-yeon, an environmental engineering professor at Yonsei University. 'There's a reason why countries maintain their own standards. In Korea, where consumers remain particularly sensitive to the radon issue, trust is directly tied to obtaining domestic safety approval.' Cho added that even if Sealy's mattresses do not contain anion stones — such as monazite, the radioactive material used by Daijin Bed — all mattresses and bed frames are potentially susceptible to radon exposure. 'Even wooden beds can be a source of radon if they use certain materials or construction methods that allow for radon infiltration,' he said. Among other major mattress brands, Korea's Ace Bed has not obtained radon certification since 2021. Meanwhile, companies like Tempur Korea, Sono Season and Allerman Spinks have yet to receive any radon-related approvals. Emphasizing the need for stricter oversight, Cho said, 'Developed countries have radon safety frameworks guided by organizations such as the US EPA and European regulatory bodies. Typically, local governments and private associations adopt these guidelines and develop their own systems, which are cross-verified to ensure proper implementation.'
Korea Herald
19-05-2025
- Korea Herald
Loneliness hits 62% of solo households in Seoul, city steps up care programs
More than 6 in 10 people living alone in Seoul say they often feel lonely, and over 1 in 8 report having no one to turn to in times of real need, according to a new study released Monday. A survey of 3,000 single-person households by the Seoul Institute, a think tank funded by the city, found that 62.1 percent of respondents experience persistent loneliness. Another 13.6 percent fall into what researchers classify as social isolation: individuals with no support network when they are emotionally distressed, physically unwell or in sudden financial trouble. The problem is especially stark among middle-aged men. In the 40 to 64 age group, 66 percent reported loneliness, and 15.8 percent were socially isolated. Marital status was also a major factor. Those who were married but living alone were the most likely to feel lonely, at 68.6 percent, followed by the widowed (66.8 percent), divorced or separated (63.8 percent) and never-married (59.6 percent). These findings were based on the UCLA Loneliness Scale. This is a common psychological tool that identifies loneliness through 20 self-assessment items, with a total score ranging from 20 to 80. For this study, a score above 43 was categorized as lonely. National figures reinforce the trend. South Korea's official 2024 Social Indicators report, published by Statistics Korea in March, found that 21.1 percent of the population feels lonely, up from 18.5 percent a year earlier. The share of people who say 'nobody really knows me' also rose to 16.2 percent. The stakes are serious. South Korea recorded 3,662 cases of 'lonely deaths' in 2023, or people who died alone without family or support. Men accounted for 84 percent of those cases, with more than half in their 50s or 60s, according to the Ministry of Health and Welfare. In response, Seoul launched a five-year, 451.3 billion won ($322 million) plan in October called 'Seoul Without Loneliness.' It includes emotional support hotlines, early detection systems and in-person care services. One key service, the 'Goodbye Loneliness 120' phone line, received more than 3,000 calls between April 1 and May 8. By dialing 120 and selecting option 5, residents can speak with trained counselors 24 hours a day for emotional support or referrals to additional services. Most callers were middle-aged adults (59 percent), followed by young people (32 percent) and seniors (8 percent). The city is also testing out 'Seoul Maeum Convenience Stores,' which are community spaces in four districts where any resident can drop in for a free bowl of ramen and talk to trained staff or volunteers. Since March, more than 4,400 people have visited. Mayor Oh Se-hoon visited one Friday in Dongdaemun and said the program is still in its early stages but promised to expand it so 'anyone struggling emotionally has a place to go.'
Korea Herald
18-05-2025
- Korea Herald
Access to breakthrough medicines in South Korea among slowest globally, industry report reveals
New drugs account for just 13.5 percent of South Korea's drug spending, less than half the OECD average New medicines may be hitting global markets at record speed, but for South Korean patients, they remain largely out of reach, often for years after their initial approval overseas. According to a 2025 report by the Korea Research-based Pharmaceutical Industry Association, only 5 percent of new drugs launched globally are available in South Korea within the first year. That's far below the OECD average of 18 percent, and significantly behind Japan's 32 percent. Delays are compounded after approval. The same KRPIA analysis, which reviewed 460 drugs approved in the US, Europe and Japan from 2012 to 2021, found that it takes an average of 28 months for South Korean regulators to approve new medicines. It takes another 18 months on average for those drugs to gain insurance coverage, meaning a total wait of nearly four years before patients can access treatments under the national health system. In contrast, Germany averages just 11 months and Japan 17 months for the same process. Pricing policy is a key reason. In South Korea, new drug prices are tied to the cost of older, similar treatments. Many older drugs are already priced low, limiting what pharmaceutical companies can charge, even for medications that show superior results. KRPIA points out that when generics enter the market, prices can drop by over 50 percent, and most new drugs end up priced at or below 90 percent of those benchmarks. Without room to negotiate, many companies choose not to launch their newest drugs in South Korea. As a result, spending on innovative treatments remains low. A 2024 study by Professor Yoo Seung-rae at Dongduk Women's University found that from 2017 to 2022, only 13.5 percent of South Korea's total health insurance drug budget went toward new medicines. That's 2.5 times lower than the OECD average of 33.9 percent. In March, the Ministry of Health and Welfare announced a new pricing model to ease this bottleneck. The so-called 'dual pricing' system allows companies to set a higher public list price while refunding the difference to the national insurer. Officials hope this will encourage more drug launches, especially from companies aiming to use Korean prices as export benchmarks. But challenges remain, particularly for combination therapies, most of which are used in cancer treatment. While such regimens are becoming standard in countries like the United States, they often remain unreimbursed in South Korea, especially when the drugs come from different manufacturers. Between 2020 and 2024, 53 combination therapies applied for expanded reimbursement, but only one cross-company case (Braftovi and Erbitux for colorectal cancer) was approved, according to data from the Health Insurance Review and Assessment Service. That means even when international studies show major survival benefits, as with recent combinations for bladder and lung cancers, South Korean patients may have no way to access them through the public system. KRPIA warns that without broader reforms, South Korea risks falling further behind in providing timely access to breakthrough treatments.
